Before Berkshire Hathaway's acquisition announcement on May 31, 2026, several prominent Wall Street analysts had price targets for Taylor Morrison Home Corporation (TMHC) clustered around the $80 mark. Truist Financial maintained an $80 target on the stock in April 2026, while Berkshire Hathaway (BRK.B) competitor Wedbush carried an $85 target. These projections reflected confidence that TMHC's diversified homebuilding platform — spanning entry-level, move-up, resort lifestyle, and build-to-rent segments — could command a higher valuation multiple as the housing cycle stabilized.
The $80 level gained additional resonance because it represented a psychological round number and aligned with TMHC's tangible book value trajectory. Before the deal, the stock traded near $58.50, meaning the $80 target implied roughly 37% upside — ambitious but not implausible given the company's strong balance sheet and share repurchase program.
On May 31, 2026, Berkshire Hathaway and Taylor Morrison jointly announced a definitive agreement under which Berkshire would acquire the homebuilder for $72.50 per share in cash, valuing TMHC's equity at approximately $6.8 billion and total enterprise value at roughly $8.5 billion. The offer represented a 24% premium to TMHC's closing price of $58.50 on May 29, 2026. The transaction, expected to close in the second half of 2026 pending shareholder and regulatory approvals, will take TMHC private and delist its shares from the New York Stock Exchange.
For the $80 question, this deal fundamentally alters the calculus. In a standard cash acquisition, the offer price acts as a magnetic ceiling: arbitrageurs and institutional investors quickly close the gap between the market price and the deal price, leaving virtually no room for upside beyond the agreed terms. Following the announcement, TMHC shares surged approximately 22% in a single session, settling within pennies of $72.50, where they have remained. The stock was subsequently delisted on July 24, 2026.
Several analysts immediately recalibrated. Truist Financial lowered its target from $80 to $72.50. RBC Capital moved to $72.50 with a Sector Perform rating. Raymond James, Wolfe Research, and Citizens JMP each downgraded TMHC to Hold-equivalent ratings, effectively acknowledging that standalone valuation analysis had been superseded by deal mechanics.
To understand why $80 was considered realistic before Berkshire's intervention, it is worth examining the company's underlying performance. In its first-quarter 2026 earnings, Taylor Morrison reported adjusted earnings per share (EPS) of $1.12, handily beating consensus estimates of $0.82, on revenue of $1.39 billion. While revenue declined 26.8% year-over-year — reflecting broader housing affordability headwinds and elevated mortgage rates — the company demonstrated operational discipline.
Key metrics that supported a bullish standalone case included a 23% sequential increase in sold backlog to 3,465 homes, a shift toward higher-margin to-be-built sales (rising to 38% of orders from 28% in the prior quarter), and a 30% reduction in finished unsold spec inventory. The company also maintained $1.6 billion in liquidity and reaffirmed full-year guidance for approximately 11,000 home closings at an average price of $580,000 to $590,000, alongside $400 million in planned share repurchases.
With a trailing price-to-earnings (P/E) ratio of roughly 10x and a price-to-book value near 1.1x before the deal, TMHC traded at a discount to many homebuilding peers. Bullish analysts argued that a re-rating toward a 12–14x P/E multiple — supported by margin resilience, share buybacks, and demographic tailwinds — could justify an $80 stock price over a 12-to-18-month horizon.
Although the probability appears low, there are theoretical paths through which TMHC shares could trade above the $72.50 deal price. The first is a competing acquisition proposal. The merger agreement includes customary fiduciary-out provisions allowing Taylor Morrison's board to consider superior offers, though a termination fee and Berkshire's unmatched financial resources make a bidding war unlikely.
The second scenario involves deal termination. If regulatory hurdles emerge or shareholder approval falls short, TMHC would resume trading on its standalone merits. In that case, the pre-deal bull case — anchored by backlog momentum, capital returns, and an undemanding valuation — would reactivate, and the $80 target could regain relevance.
A third, narrower possibility involves appraisal rights. Under Delaware law, dissenting shareholders who follow proper procedures can seek a judicial determination of fair value, which could theoretically exceed $72.50. However, appraisal proceedings are costly, time-consuming, and historically rarely result in materially higher valuations for widely covered public companies.
According to data from MarketBeat, the consensus 12-month analyst price target for TMHC stood at $77.43 as of July 2026, with a range spanning from $68.00 to $95.00. However, it is critical to note that many of these targets were issued or maintained before the Berkshire deal was fully priced in. Post-announcement, the active targets clustered tightly around $72.50, with Barclays raising its target modestly to $73.00 and most other firms aligning with the deal price. The consensus rating across 11 analysts shifted decisively to Hold, with nine Hold ratings and two Buy ratings, compared to a predominantly bullish stance earlier in 2026.
TipRanks data showed an average price target of $66.38 from eight analysts covering the stock in the most recent three-month period, with a high of $72.50 — reflecting how the deal has compressed all targets toward the acquisition price. Seaport Global, which had previously carried an $85 target, downgraded TMHC to Sell with a $49 target in early April 2026, highlighting the wide dispersion of views before the Berkshire announcement effectively resolved the debate.
In a market environment where corporate events such as acquisitions can rapidly reshape a stock's outlook, traders increasingly turn to technology-driven tools for timely guidance. Tickeron's AI Daily Buy/Sell Signals product leverages artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving technical patterns, market conditions, and AI-powered analysis. These signals help traders screen for emerging opportunities, track positions more effectively, and identify shifts in market sentiment before they become widely recognized. For investors navigating complex situations like pending mergers, such tools can provide an additional layer of data-driven insight to complement traditional fundamental and technical research.
The question of whether Taylor Morrison Home Corporation can reach $80 per share must now be evaluated through the lens of the Berkshire Hathaway acquisition. Under normal standalone trading conditions, TMHC's improving backlog, disciplined cost management, conservative valuation, and significant share repurchase program provided a credible foundation for the stock to approach that level over time — as several analyst targets confirmed. However, the definitive all-cash acquisition agreement at $72.50 per share has effectively rendered the $80 target unattainable under the current deal structure. The stock is capped at the offer price, and only a competing bid, deal termination, or successful appraisal challenge could reopen the path higher. Investors monitoring this situation should focus on deal-closing milestones, any regulatory developments, and the remote but non-zero possibility of a superior proposal emerging before the transaction is finalized in the second half of 2026.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TMHC has been closely correlated with MHO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMHC jumps, then MHO could also see price increases.
| Ticker / NAME | Correlation To TMHC | 1D Price Change % | ||
|---|---|---|---|---|
| TMHC | 100% | N/A | ||
| MHO - TMHC | 74% Closely correlated | -0.79% | ||
| MTH - TMHC | 74% Closely correlated | -1.26% | ||
| KBH - TMHC | 68% Closely correlated | -3.34% | ||
| HOV - TMHC | 59% Loosely correlated | -1.43% | ||
| BZH - TMHC | 49% Loosely correlated | +0.03% | ||
More | ||||